|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||
  EpilepsiaVolume 40 Issue 2, Pages 190 - 196 Published Online: 2 Aug 2005 © 2010 International League Against Epilepsy Published on behalf of the International League Against Epilepsy (ILAE)
Abstract | References | Full Text: PDF (Size: 649K) | Related Articles | Citation Tracking  Adjustment of Carbamazepine Dose to Offset the Effects of the Interaction with Remacemide Hydrochloride in a Double-Blind, Multicentre, Add-On Drug Trial (CR2237) in Refractory Epilepsy Copyright 1999 International League Against Epilepsy KEYWORDS Carbamazepine • Remacemide • Interaction • Shewart control chart ABSTRACTSummary: Purpose: The efficacy of remacemide hydrochloride (REM) as an antiepileptic drug (AED) was tested in a double-blind, add-on trial in patients with refractory epilepsy. Concurrent drugs included carbamazepine (CBZ). The interfering effects of the pharmacokinetic interaction between REM and CBZ were offset by the monitoring of plasma CBZ concentration and the appropriate reduction of CBZ dose by an unblinded observer. Methods: Patients taking CBZ entered a 4-week run-in period to stabilise their dosage regimen to Tegretol tablets and blinded capsules containing Tegretol tablets. They then entered an 8-week baseline period during which variation of plasma CBZ concentration was used to derive an individual Shewart Control Chart for each patient. These charts were used to define the threshold for CBZ dose reduction after the addition of trial drug. Where necessary the unblinded observer adjusted that portion of the daily dose of CBZ concealed in the opaque capsules, thereby maintaining the blind for the investigator and the patient. Results: CBZ dosage reductions ranging from 14 to 50% were required by 63% of patients who received REM. Substantial increases in plasma CBZ concentration, which would have confounded the results of the trial, were thus avoided. The small increases in CBZ concentration that occurred in spite of this procedure were of similar magnitude in responders (patients who experienced ≤50% reduction in seizure frequency during treatment) and nonresponders, and in both groups the mean increase was <1 mg/L. Conclusions: The method is offered as a model solution for problems caused by pharmacokinetic interactions in add-on trials. Accepted September 9, 1998. | 
|
